

Imaging therapeutic radiopharmaceuticals in mice using the MACACO III+ Compton camera

K. Brzezinski¹, L. Barrientos¹, J. V. Casaña¹, I. Aiestaran², U. Cossio², J. Llop² and G. Llosá¹

1. Instituto de Física Corpuscular (IFIC), CSIC-UV, Spain.

2. CIC biomaGUNE, Basque Research and Technology Alliance (BRTA), San Sebastián, Spain.

Overview

- Preclinical imaging targeted radionuclide therapy (TRT)
- MACACO III+ Compton camera
- Imaging ^{131}I in mice at CIC biomaGUNE
- Prospects for ^{225}Ac imaging in small animals
- Conclusions


Preclinical imaging for TRT

- Development of translational radioisotope therapies in murine models
- Dedicated pre-clinical SPECT systems are not optimal (designed for <300 keV)
 - low efficiency
 - high energy of the photons emitted by radioisotopes, ex. ^{131}I (364 keV), ^{225}Ac (440 keV)
- Compton camera solution:
 - Higher efficiency due to electronic collimation
 - Superior response to high-energy photons
 - Better suited for multi-gamma imaging



Compton camera

Registration of successive interactions of the incident photons in position-sensitive detectors




Determination of the Compton scattering angle through Compton kinematics

$$\cos \varphi = 1 - m_0 c^2 \left(\frac{1}{E_{\gamma'}} - \frac{1}{E_{\gamma}} \right)$$

$$E_{\gamma} = E_{e^-} + E_{\gamma'}$$

Reconstruction of the origin of the incident gamma ray through backprojection of cones of response CoRs:




+ Image reconstruction

List mode ML-EM


$$\lambda_j^{n+1} = \frac{\lambda_j^n}{s_j} \sum_{i=0}^N \frac{t_{ij}}{\sum_k t_{ik} \lambda_k^n}$$

MACACO III (Medical Applications CompAct COmpton camera)


Detectors




Readout



Hybrids




AliVATA DAQ board






Commercialized
by Alibava
Systems S. L.

Improved Sensitivity with MACACO III+

MACACO III





MACACO III+



Imaging ^{131}I -NaI in mice

Measurements at CIC biomaGUNE (San Sebastian)



Mouse phantom

Two 45 min measurements

- brain + kidney (2.95 MBq/ml)
- brain+ kidneys + heart + bladder (2.55 MBq/ml) (3.99 MBq/ml)

Comparison with commercial SPECT
Molecubes γ -CUBE (3 hours)

Live mice

30 min measurements

- Two mice: 30.46 g and 29.06 g
- 1.20 MBq/ml and 2.16 MBq/ml

Mouse Phantom with ^{131}I

γ -CUBE 3 hrs MACACO III+ 45 min

γ -CUBE 3 hrs MACACO III+ 30 min

Mouse Phantom with ^{131}I

γ -CUBE 3 hrs

MACACO III+ 45 min

γ -CUBE 3 hrs

MACACO III+ 30 min


Actinium-225 imaging for TAT

TAT: Efficient tumour control, sparing healthy tissue

- high linear energy transfer (LET)
- short range (<100 μm , a few cell diameters)

^{225}Ac : Promising alpha-emitters

- high net alpha yield
- high alpha energies
- 10 day half-life



Multi-isotope imaging application

Toxicity to non-target and excretion organs due to difficulty of targeting cells with the entire decay chain

Ex. Renal toxicity due to ^{213}Bi

Challenges for ^{225}Ac Imaging

1) High alpha yield of ^{225}Ac requires small therapeutic doses, limiting signal for gamma imaging

Ex. Comparison of ^{177}Lu]Lu-PSMA-I&T vs. ^{225}Ac]Ac-PSMA-I&T*

2) 440 keV challenging for gamma camera

	^{177}Lu]Lu-PSMA-I&T	^{225}Ac]Ac-PSMA-I&T
Therapeutic Activity	7.4 GBq	8 MBq
Photon yield	208 keV (10%) 113 keV (6%)	218 keV (11%) 440 keV (26%)

Activity concentrations

Clinical**:

- Median viable tumour volume: 35.7 mL
- Minimum activity: 10 MBq -> **280 kBq/mL**

Preclinical***:

- **40 kBq/mL** (EC_{50})


Low activity!

*Dekler et al. EJNMMI (2023) 50:1280–1290

**Patients with in glioblastoma treated with ^{225}Ac]Ac-DOTA-substance P, Tulik et al. EJNMMI Physics (2024) 11:41

**Rodak et al. Mol Cancer Ther. 2022 Sep 21;21(12):1835–184


Imaging ^{225}Ac with MACACO III



Measurements at Léon Bérard hospital in Lyon

Imaging ^{225}Ac in mice (simulations)


Digimouse: 3D Mouse Atlas*



From ^{225}Ac biodistributions in live mice*
25 kBq injected activity (IA)

Tissue/organ	mean % IA/g 6 hrs p.i.
Liver	0.32
Spleen	0.17
Lungs	0.05
Heart	0.05
Stomach	0.04
Kidneys	10.31
Pancreas	0.08
Bone	0.09
Tumor (200 mm³)	9.87

*M. Rodak et al., Mol Cancer Ther, 21(12), 1835–1845, 2022



Conclusions

- LaBr_3 -based Compton camera proposed for preclinical imaging for TRT.
- Images of ^{131}I in mice obtained with MACACO III+ are comparable to those obtained using a commercial preclinical SPECT system, in less time.
- Encouraging initial results for ^{225}Ac imaging at Léon Bérard hospital in Lyon.
- Simulations show possibilities of imaging ^{225}Ac decay products mice, with low activities.
- Optimization for preclinical conditions are under way.

Acknowledgements

This work was supported by:

- MCIN /AEI (PID2022-143246OB-I00).



Thank you

karol.brzezinski@ific.uv.es